Pidnarulex Clinical Trials (2026): 5 Studies for Metastatic Malignant Solid Neoplasm & Anatomic Stage IV Breast Cancer AJCC v8
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Pidnarulex clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Metastatic Malignant Solid Neoplasm & Anatomic Stage IV Breast Cancer AJCC v8) and 260 total planned enrollment. 4 Pidnarulex clinical trials are actively recruiting at 7 U.S. sites across 5 states. Most recent activity: NCT07069699 (Jan 2030).
Where to Participate: All Pidnarulex Trial Sites in the U.S. (7 sites across 5 states)
Every actively recruiting Pidnarulextrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT07069699 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT07069699 | Map |
| MD | JHU Sidney Kimmel Comprehensive Cancer Center LAO | Baltimore21231 | NCT07147231 | Map |
| MD | National Cancer Institute Developmental Therapeutics Clinic | Bethesda20892 | NCT06606990 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT07137416 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT07069699 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT07069699 | Map |
Pidnarulex clinical trials at a glance: phase × recruitment status
| Phase | recruiting | suspended | Total |
|---|---|---|---|
| P1 | 2 | 1 | 3 |
| P1/P2 | 2 | 2 |
Recruiting Pidnarulex clinical trials (4)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | P1/P2 | Burkitt Lymphoma | 50 | Oct 2026 |
| NCT07137416 | HER2Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | P1 | Anatomic Stage III Breast Cancer AJCC v8 | 36 | Oct 2026 |
| NCT07147231 | CX-5461Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | P1/P2 | Metastatic Colorectal Adenocarcinoma | 86 | Dec 2026 |
| NCT06606990 | Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers | P1 | Metastatic Malignant Solid Neoplasm | 40 | Jul 2025 |
Pidnarulex clinical trials by indication
Metastatic Colorectal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07147231 | CX-5461 | P1/P2 | recruiting | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer |
Burkitt Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07069699 | — | P1/P2 | recruiting | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene |
Anatomic Stage III Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07137416 | HER2 | P1 | recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer |
Metastatic Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06606990 | — | P1 | recruiting | Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers |
Metastatic Castration Resistant Prostate Cancer (mCRPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05425862 | REPAIR | P1 | suspended | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer |
Terminated and withdrawn Pidnarulex trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05425862suspendedPidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
All Pidnarulex trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | P1/P2 | recruiting | 50 | National Cancer Institute (NCI) | Oct 2026 | |
| NCT07137416 | HER2 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | P1 | recruiting | 36 | National Cancer Institute (NCI) | Oct 2026 |
| NCT07147231 | CX-5461 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | P1/P2 | recruiting | 86 | National Cancer Institute (NCI) | Dec 2026 |
| NCT06606990 | Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers | P1 | recruiting | 40 | National Cancer Institute (NCI) | Jul 2025 | |
| NCT05425862 | REPAIR | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | P1 | suspended | 48 | Peter MacCallum Cancer Centre, Australia | Oct 2022 |
Pidnarulex clinical trials: frequently asked questions
- How many Pidnarulex clinical trials are there?
- 5 Pidnarulex clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants.
- Are Pidnarulex clinical trials recruiting in 2026?
- Yes — 4 Pidnarulex trials are actively recruiting in 2026, with 7 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pidnarulex being studied for?
- Pidnarulex is being studied for Metastatic Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8, Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements and 20 more. The trials are grouped by indication on this page.
- What phase is Pidnarulex in?
- Pidnarulex clinical trials span 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pidnarulex clinical trials?
- The lead sponsor across the most Pidnarulex trials is National Cancer Institute (NCI), with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pidnarulexas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: